| Previous close | 135.85 |
| Open | 135.75 |
| Bid | 136.35 x 0 |
| Ask | 139.30 x 0 |
| Day's range | 134.15 - 138.55 |
| 52-week range | 65.40 - 138.55 |
| Volume | |
| Avg. volume | 161,864 |
| Market cap | 27.916B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 80.71 |
| EPS (TTM) | 1.70 |
| Earnings date | 24 Jul 2024 - 03 Aug 2024 |
| Forward dividend & yield | 1.33 (1.84%) |
| Ex-dividend date | 28 Apr 2023 |
| 1y target est | N/A |
PR NewswireNew CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
UCB, a global biopharmaceutical company, will present results from three studies for CIMZIA® (certolizumab pegol), a PEGylated fragment crystalized (Fc)-free tumor necrosis factor inhibitor (TNFi), for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels.1,2,3 These data will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment dec
PR NewswireUCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension (OLE), BE MOVING, evaluating BIMZELX, an interleukin (IL)-17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis. The impact of BIMZELX treatment on two-year radiographic progression in
PR NewswireUCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
UCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).1 This article represents the primary publication of BIMZELX data from the two pivotal Phase 3 HS studies. HS is one of the most burdensome, chronic, systemic, inflammatory s
